| Prev Close | 68.51 |
| Day Low/High | 67.92 / 69.17 |
| 52 Wk Low/High | 60.89 / 85.97 |
Gilead Sciences, Inc. (GILD)
68.10
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 1253.72B |
| Market Cap | 85.89B |
| P/E Ratio | 17.57 |
| Div & Yield | N.A. (N.A) |
The Market Refuses to Embrace Negatives as Major Earnings Reports Roll In
So far, earnings season has not been the obstacle that many have feared.
Vulnerable Markets, Reopening the Economy, Trading PepsiCo: Market Recon
This week the Bureau of Economic Analysis will release its very first estimate for first quarter U.S. economic growth on a quarter over quarter, annualized, and then seasonally adjusted basis.
Nothing Seems to Bother This Market Right Now, Certainly Not Earnings
It is hard to fully understand how the worst economic crisis we have ever seen is not creating more pressure on stocks.
Indian Generic Maker Glenmark Seeks to Make Japanese Covid-19 Drug
India's drugmakers aim to manufacture generic versions of any coronavirus 'cure', even before the full findings as to how effective they are.
Saving the Service Economy, Gilead Trials and Intel's Earnings: Market Recon
More government funding is approved to fight Covid-19 layoffs, Gilead sells off on early reports around China trials and Intel announces earnings.
This Sentiment Survey Is Not a Bunch of 'Bull'
I have been following this indicator for more than 20 years and have always spent a fair bit of time scoffing at it, but let's look at this one's results.
Keep Your Eyes on Earnings
Overall, the indexes are muddled and clarity is lacking on the economy, but earnings should influence the next major market move.
Cramer: The Stock Market Is Now Divided Into 3 Buckets - And One Is Unfortunate
The problem for index fund owners is they own all three buckets and there are a lot more companies in the third bucket than in the first two.
Takeaways for a Not-so-Great Day
It was another day in which there was some bad news out of Gilead and the bad economic data continues. From my perch, Mr. Market is doing a good job of consolidating a spectacular gain from the mid-March bottom. * Oil +$3.20/barrel. (And energy stoc...
What the Bears Want
In Twitter feeds I can feel the Bears rooting for the markets to go down. (While anything can happen) I am not so sure it's going to happen today - even with the Gilead news. I will end the day longer than I started the day.
Jim Cramer: This Market Values Companies With a Heart
Brains per share. Hearts Per Share. I've been around long enough to be that positive. I like these companies and more importantly, I like their stocks.
Mid-Caps Outperform, Funding 'Paycheck Protection', U.K. Vaccine Trials
Trading volumes dropping on major indexes, U.K. teams begin human trials on a Covid-19 vaccine, and the U.S. Senate wants another stimulus package addition.
How I See Market Performance Evolving Over Time, Trading Advanced Micro
Will tech continue to trend toward leadership? Who among us can remember when it has not?
The Week Ahead: Jobless Claims, PMI Data and 35 Key Earnings Reports to Watch
More than 450 quarterly reports are on tap, including 105 S&P 500 constituents.
Gilead, Costco and Amazon: 3 Top Pandemic Stocks for DRIP Investors
Long-term investors must buy during bear markets -- and these companies offer dividend reinvestment or direct investment plans to help seize the opportunity.
Jim Cramer: I'm Very Concerned About a Breakdown in Oil Here
I have to believe that a few more weeks of lower oil prices and we will see more bankruptcy filings.
We're at a Crossroads and Friday's Close Is Going to Be Huge
Today is about hope on two fronts: the markets and society.
Maintaining Optimism in a Surreal Pandemic Environment
I never understood why my state of Florida, with vastly fewer deaths, is on the same sort of lockdown as New York.
Gilead Surges on Remdesivir Report: How to Play the Stock Now
We have a new price target for GILD.
Shorting Apple ($289.75 pre-market trading)
* For investment and placing stock on my Best Ideas List I'll get into the tactical moves I made last night (after the S&P futures rose by nearly +90 handles in response to the Gilead Sciences drug news), but I wanted to mention that I am shorting A...
Less Gold
From early last night - I sold down my position based on "The Smartest Trader" comments that the rise in gold was looking "tired", the reduced reward vs. risk (short term), and because of the positive equity impact on the Gilead drug announcement (a...
Bears Are Capitulating but This Still Is Just a Very Large Counter-Trend Bounce
There is likely to be some period of consolidation as market players assess the many crosscurrents that are occurring.
Futures Pop, Gilead's Covid-19 Treatment, Trading My 'Virus Group'
The rise in equity futures pricing was born of optimism from the president's task force draft guideline on reopening parts of the U.S. economy and Gilead Sciences' somewhat positive results on its remdisivir anti-viral treatment.
This Market Has Been Rangebound on Derivatives Exposure
Friday is the April expiration for S&P 500 index options -- and that can explain more or less why the market has been so tightly pinned.
My New Multi-Group Portfolio Strategy for Trading the Pandemic
How has my book evolved since the Fed and Treasury rode into town? Here's how.
Jim Cramer: Don't Mistake the Rally for Cheering
There is no joy in stockville -- instead we have big companies with stocks rising. Here's why that is and what you need to understand about the rally amid the crisis.
Inflationary Concerns, Banks Report Earnings, Netflix Soars: Market Recon
I did warn publicly back in another epoch that quantitative easing would lead toward increased consumer level inflation.
Jim Cramer: Now We're Seeing a Work in Progress
As testing expands, drug trials proceed and tech greats are providing a tracking app, I think we're inching toward going back to work -- and further away from going so low again.
